Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Hurel Announces 3-D Tissue Construct Grant Program

By Drug Discovery Trends Editor | September 27, 2013

Hurel Corporation (North Brunswick, N.J.), a leading developer of cell-based tissue constructs and microfluidic assay platforms, which can improve the speed and accuracy of pre-clinical prediction in drug development, announced an ambitious new research grant program to spur innovation in the use of its cell-based models in pharmaceutical and industrial toxicological research. The company said it is prepared to commit in aggregate up to $150,000 under the grant program, and that it intends to invite qualified academic research scientists to submit funding proposals for projects that will seek to trail-blaze new uses and applications for Hurel’s high-functioning, long enduring hepatic tissue cultures.
 
Hurel focuses on the production of 3-D tissue cultures that simulate and predict the in vivo function of the liver and other organs.  The company recently launched its Hurelhuman, Hureldog and Hurelrat product lines, which are created from the primary liver cells of the respective species.  Hureldog is the first characterized, 3-D tissue culture product based on primary liver cells from the canine species.
 
“Over the past three decades, my colleagues and I have developed and tested several different hepatic tissue constructs, many of which are utilized by researchers today, such as gel-overlay hepatocyte cultures and micropatterned co-cultures,” said Martin Yarmush, MD, PhD, Hurel’s chief scientific adviser.  “In the evolution of these hepatic models, the Hurel co-culture is the first that we deliberately engineered for use in industrial scientific research, where manufacturing efficiency, ability to replicate results, and ease of use in the lab are virtues of an importance equal to that of the cellular competency of the model itself. With such a ‘workhorse’ platform in hand, we are intensely curious to see how our academic colleagues, drawing on their knowledge and their scientific imaginations, may seek to probe its capabilities and push the envelope of its potential applications.”
 
The formal Call for Proposals document is currently being finalized and Hurel anticipates releasing it in late October, 2013.  
 
 
Date: September 26, 2013
Source: Hurel Corporation

Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE